Titre : | Patients admitted for inpatient cannabis detoxification: withdrawal symptoms and impacts of common comorbidities (2011) |
Auteurs : | G. M. DAWES ; T. SITHARTHAN ; K. M. CONIGRAVE ; N. PHUNG ; M. WELTMAN |
Type de document : | Article : Périodique |
Dans : | Journal of Substance Use (Vol.16, n°5, October 2011) |
Article en page(s) : | 392-405 |
Langues: | Anglais |
Discipline : | PSY (Psychopathologie / Psychopathology) |
Mots-clés : |
Thésaurus mots-clés DESINTOXICATION ; CANNABIS ; SEVRAGE ; ETUDE CLINIQUE ; COMORBIDITE ; PSYCHOPATHOLOGIE ; PRISE EN CHARGE ; SYNDROME DE SEVRAGE ; CURE DE DESINTOXICATIONThésaurus géographique AUSTRALIE |
Résumé : |
Introduction: There is clinical impetus to accurately monitor cannabis withdrawal symptoms. In doing this the impact of other drug and mental health comorbidities should be considered.
Aims: To report patient demographics, psychiatric and substance use comorbidities and symptoms of cannabis withdrawal in the first 5 days of hospital admission for detoxification. Design: Daily self-reported symptom severity ratings were analysed as functions of gender, secondary drug use and recent mental health history. Setting: Specialised inpatient hospital unit for withdrawal management (detoxification) at a University of Sydney teaching hospital, Sydney, Australia. Participants: Total 193 consecutive patients admitted for routine inpatient cannabis withdrawal management over a 9-month period. Measurements: Patients screened via daily self-reported subjective ratings of cannabis withdrawal. Findings: Average cannabis used per day was 2.6 g. Most patients smoked tobacco daily (91%) and half of the sample (53%) reported other drug use. Alcohol was the main secondary drug used (29%). Half of the patients (51%) reported recent contact or interventions for mental health concerns. We were able to delineate principal withdrawal features to include "anxiety" (physical tension, hypermentation, palpitations and excessive worry), dysphoria (+ anergia, anhedonia, lethargy and somnolence) and irritability/agitation. Additional features identified included mood swings and cravings for cannabis. These features all significantly declined over a 5-day admission. Recent mental health concerns, but not gender or secondary drug use, correspond to greater global symptom severity over the course of admission. Conclusions: This study underscores a need to be alert to the impacts of comorbidities that are common in this treatment-seeking population, especially secondary drug use and the potential for mental health issues which add dimensions of complexity. |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | Department of Addiction Medicine (Nepean, Westmead Hospitals), NSW Health, New South Wales, Sydney, Australia |
Lien : | http://dx.doi.org/10.3109/14659891.2010.499491 |
Accueil